Evidence map›Paper›PMID 31336701›Full record

ReviewCancers2019

Prognostic Role of miR-221 and miR-222 Expression in Cancer Patients: A Systematic Review and Meta-Analysis.

Gloria Ravegnini, Sarah Cargnin, Giulia Sammarini, Federica Zanotti, Justo Lorenzo Bermejo, Patrizia Hrelia, Salvatore Terrazzino, Sabrina Angelini

Abstract readReview
In one paragraph

Review in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Decarbromodiphenyl ether exposure promotes migration of triple-negative breast cancer cells through miR-221 in extracellular vesicles.Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2024
    Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. MicroRNA in adenoid cystic carcinoma (Review).International journal of oncology · 2023
    Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Gloria RavegniniDepartment of Pharmacy and Biotechnology, University of Bologna, 40126 Bologna, Italy.ORCID 0000-0002-7774-402X
Sarah CargninDepartment of Pharmaceutical Sciences and Interdepartmental Research Center of Pharmacogenetics and Pharmacogenomics (CRIFF), University of Piemonte Orientale, 28100 Novara, Italy.
Giulia SammariniDepartment of Pharmacy and Biotechnology, University of Bologna, 40126 Bologna, Italy.
Federica ZanottiDepartment of Pharmacy and Biotechnology, University of Bologna, 40126 Bologna, Italy.
Justo Lorenzo BermejoInstitute of Medical Biometry and Informatics, University of Heidelberg, 69120 Heidelberg, Germany.
Patrizia HreliaDepartment of Pharmacy and Biotechnology, University of Bologna, 40126 Bologna, Italy.ORCID 0000-0002-8415-3711
Salvatore TerrazzinoDepartment of Pharmaceutical Sciences and Interdepartmental Research Center of Pharmacogenetics and Pharmacogenomics (CRIFF), University of Piemonte Orientale, 28100 Novara, Italy.ORCID 0000-0002-4909-1121
Sabrina AngeliniDepartment of Pharmacy and Biotechnology, University of Bologna, 40126 Bologna, Italy. s.angelini@unibo.it.ORCID 0000-0002-1609-0421

Funding

Ministero dell'Istruzione, dell'Università e della Ricerca 2015Y3C5KP_002
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

cancermiR-221miR-222overall survivalprogression-free survival

Identifiers

PMID31336701
PMCPMC6678869

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.